NCT06322667Recruiting
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
A Multicenter, Postmarketing Observational Study to Evaluate Safety Regarding Amyloid-Related Imaging Abnormalities and Their Management in Patients With Early Alzheimer's Disease and Treated With Lecanemab
Source: ClinicalTrials.gov · Last updated 23 Jan 2026
Brief summary (registry, in English)
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 5000 (estimated)
- First submitted
- 14 Mar 2024
- Start date
- 14 Feb 2024
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Eisai Co., Ltd.
- Diseases
- Alzheimer disease
- NCT number
- NCT06322667
What you commit to
- Study type: Observational
- Planned participants: 5000
- From 14 Feb 2024 to the primary completion date, 31 Dec 2027
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- All participants who are treated with lecanemab in routine clinical practice
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Eisai trial site 2 Coordinator of this site? Confirm its status | Hiroshima | Japan | Recruiting |
| Eisai trial site 3 Coordinator of this site? Confirm its status | Kyoto | Japan | Recruiting |
| Eisai trial site 1 Coordinator of this site? Confirm its status | Tokyo | Japan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.